Schmaljohn CS. Vaccines for Hantaviruses: progress and issues. Expert Rev Vaccines. 2012;11(5):511–3.

CAS  PubMed  Google Scholar 

Maes P, Clement J, Van Ranst M. Recent approaches in hantavirus vaccine development. Expert Rev Vaccines. 2009;8(1):67–76.

PubMed  Google Scholar 

Schmauohn CS, Schmauohn AL, Dalrymple JM. Hantaan virus MRNA: coding strategy, nucleotide sequence, and gene order. Virology. 1987;157(1):31–9.

Google Scholar 

Schmaljohn CS, Jennings GB, Hay J, Dalrymple JM. Coding strategy of the S genome segment of Hantaan virus. Virology. 1986;155(2):633–43.

CAS  PubMed  Google Scholar 

Schmaljohn CS. Nucleotide sequence of the L genome segment of hantaan virus. Nucleic Acids Res. 1990;18(22):6728.

CAS  PubMed  PubMed Central  Google Scholar 

Jonsson CB, Figueiredo LTM, Vapalahti O. A global perspective on hantavirus ecology, epidemiology, and disease. Clin Microbiol Rev. 2010;23(2):412–41.

CAS  PubMed  PubMed Central  Google Scholar 

Clement J, Maes P, Van Ranst M. Hemorrhagic fever with renal syndrome in the new, and hantavirus pulmonary syndrome in the Old World: paradi(se)gm lost or regained? Virus Res [Internet]. 2014;187:55–8. https://doi.org/10.1016/j.virusres.2013.12.036.

CAS  Article  Google Scholar 

Alexeyev OA, Baranov BA. Puumala virus infection without signs of renal involvement. Scand J Infect Dis. 1993;25(4):525–7.

CAS  PubMed  Google Scholar 

Mackow ER, Gavrilovskaya IN. Cellular receptors and hantavirus pathogenesis. Curr Top Microbiol Immunol. 2001;256:91–115.

CAS  PubMed  Google Scholar 

Gavrilovskaya IN, Brown EJ, Ginsberg MH, Mackow ER. Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by β3 integrins. J Virol. 1999;73(5):3951–9.

CAS  PubMed  PubMed Central  Google Scholar 

Ennis FA, Cruz J, Spiropoulou CF, Waite D, Peters CJ, Nichol ST, et al. Hantavirus pulmonary syndrome: CD8+ and CD4+ cytotoxic t lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness. Virology. 1997;238(2):380–90.

CAS  PubMed  Google Scholar 

Lee HW, Johnson KM. Laboratory-acquired infections with Hantaan virus, the etiologic agent of Korean hemorrhagic fever. J Infect Dis. 1982;146(5):645–51.

CAS  PubMed  Google Scholar 

Vapalahti O, Mustonen J, Lundkvist Å, Henttonen H, Plyusnin A, Vaheri A. Hantavirus infections in Europe. Lancet Infect Dis. 2003;3(10):653–61.

PubMed  Google Scholar 

Heyman P. Hantavirus infection in Europe: from virus carriers to a major public- health problem. Expert Rev Vaccines. 2009;7(2):205–17.

Google Scholar 

MacNeil A, Nichol ST, Spiropoulou CF. Hantavirus pulmonary syndrome. Virus Res [Internet]. 2011;162:138–47. https://doi.org/10.1016/j.virusres.2011.09.017.

CAS  Article  Google Scholar 

Lin X-D, Guo W-P, Wang W, Zou Y, Hao Z-Y, Zhou D-J, et al. Migration of Norway rats resulted in the worldwide distribution of Seoul hantavirus today. J Virol. 2012;86(2):972–81.

CAS  PubMed  PubMed Central  Google Scholar 

Avšič-Županc T, Saksida A, Korva M. Hantavirus infections. Clin Microbiol Infect. 2019;21:e6–16.

Google Scholar 

Martinez-valdebenito C, Calvo M, Vial C, Mansilla R, Marco C, Palma RE, et al. Person-to-person household and nosocomial transmission of Andes. Emerg Infect Dis. 2014;20(10):1629–36.

CAS  PubMed  PubMed Central  Google Scholar 

Martinez VP, Bellomo C, San Juan J, Pinna D, Forlenza R, Elder M, et al. Person-to-person transmission of Andes virus. Emerg Infect Dis. 2005;11(12):1848–53.

PubMed  PubMed Central  Google Scholar 

Huggins JW, Kim GR, Brand OM, Mckee KT. Ribavirin therapy for Hantaan virus infection in suckling mice. J Infect Dis. 1986;153(3):489–97.

CAS  PubMed  Google Scholar 

Safronetz D, Haddock E, Feldmann F, Ebihara H, Feldmann H. In vitro and in vivo activity of Ribavirin against Andes virus infection. PLoS One. 2011;6(8)e23560. https://doi.org/10.1371/journal.pone.0023560.

Ogg M, Jonsson C, Camp J, Hooper J. Ribavirin. Protects Syrian hamsters against lethal hantavirus pulmonary syndrome — after intranasal exposure to Andes. Virus. 2013;5(11):2704–2720. https://doi.org/10.3390/v5112704.

Mertz GJ, Miedzinski L, Goade D, Pavia AT, Hjelle B, Hansbarger CO, et al. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis. 2004;39(9):1307–13.

CAS  PubMed  Google Scholar 

Chapman LE, Mertz GJ, Peters CJ, et al. City SL. Intravenous ribavirin for hantavirus pulmonary syndrome : safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther. 1999;4(4):211–219. http://www.ncbi.nlm.nih.gov/pubmed/10723500.

• Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis. 1991;164:1119–27 Clinical trail has proved that intravenous ribavirin was effective against HFRS.

CAS  PubMed  Google Scholar 

Malinin OV, Platonov AE. Insufficient efficacy and safety of intravenous ribavirin in treatment of haemorrhagic fever with renal syndrome caused by Puumala virus. Infect Dis (Auckl). 2017;49(7):514–20.

CAS  Google Scholar 

Safronetz D, Falzarano D, Scott DP, Furuta Y, Feldmann H, Gowen BB. Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother. 2013;57(10):4673–80.

CAS  PubMed  PubMed Central  Google Scholar 

Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother. 2007;51(9):3168–76.

CAS  PubMed  PubMed Central  Google Scholar 

Murphy ME, Kariwa H, Mizutani T, Tanabe H, Yoshimatsu K, Arikawa J, et al. Characterization of in vitro and in vivo antiviral activity of lactoferrin and ribavirin upon hantavirus. J Vet Med Sci. 2001;63(6):637–45.

CAS  PubMed  Google Scholar 

Murphy ME, Kariwa H, Mizutani T, Yoshimatsu K, Arikawa J, Takashima I. In vitro antiviral activity of lactoferrin and ribavirin upon hantavirus. Arch Virol. 2000;145(8):1571–82.

CAS  PubMed  Google Scholar 

Peters CJ, Zaki SR. Role of the endothelium in viral hemorrhagic fevers. Crit Care Med. 2002;30(5):S268–S273. https://doi.org/10.1097/00003246-200205001-00016.

Gavrilovskaya IN, Gorbunova EE, Mackow NA, Mackow ER. Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphingosine 1-phosphate inhibit hantavirus-directed permeability. J Virol. 2008;82(12):5797–806.

CAS  PubMed  PubMed Central  Google Scholar 

Shrivastava-Ranjan P, Rollin PE, Spiropoulou CF. Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. J Virol. 2010;84(21):11227–34.

CAS  PubMed  PubMed Central  Google Scholar 

Gorbunova EE, Gavrilovskaya IN, Pepini T, Mackow ER. VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability. J Virol. 2011;85(5):2296–303.

CAS  PubMed  Google Scholar 

Sundström KB, Hoang ATN, Gupta S, Ahlm C, Svensson M, Klingström J. Andes hantavirus-infection of a 3D human lung tissue model reveals a late peak in progeny virus production followed by increased levels of proinflammatory cytokines and VEGF-A. PLoS One. 2016;11(2):1–12.

Google Scholar 

Bird BH, Shrivastava-Ranjan P, Dodd KA, Erickson BR, Spiropoulou CF. Effect of vandetanib on Andes virus survival in the hamster model of Hantavirus pulmonary syndrome. Antiviral Res [Internet]. 2016;132:66–9. https://doi.org/10.1016/j.antiviral.2016.05.014.

CAS  Article  Google Scholar 

Grande E, Kreissl MC, Filetti S, Newbold K, Reinisch W, Robert C, et al. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther. 2013;30(11):945–66.

CAS  PubMed  PubMed Central  Google Scholar 

Hooper JW, Ferro AM, Wahl-Jensen V. Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes Virus. J Virol. 2008;82(3):1332–8.

CAS  PubMed  Google Scholar 

Brocato R, Josleyn M, Ballantyne J, Vial P, Hooper JW. DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS). PLoS One. 2012,7(4):e35996. https://doi.org/10.1371/journal.pone.0035996.

Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J Virol. 2003;77(18):9894–905.

CAS  PubMed  PubMed Central  Google Scholar 

Haese N, Brocato RL, Henderson T, Nilles ML, Kwilas SA, Josleyn MD, et al. Antiviral biologic produced in DNA vaccine/ goose platform protects hamsters against hantavirus pulmonary syndrome when administered post-exposure. PLoS Negl Trop Dis. 2015;9(6):1–19.

Google Scholar 

Vial PA, Valdivieso F, Calvo M, Rioseco ML, Riquelme R, Araneda A, et al. A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus. Antivir Ther. 2015;20(4):377–86.

CAS  PubMed  Google Scholar 

Garrido JL, Prescott J, Calvo M, Bravo F, Alvarez R, Salas A, et al. Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo. Sci Transl Med [Internet]. 2018;10(468):eaat6420. https://doi.org/10.1126/scitranslmed.aat6420.

CAS  Article  Google Scholar 

Chung DH, Kumarapperuma SC, Sun Y, Li Q, Chu YK, Arterburn JB, et al. Synthesis of 1-β-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus. Antivir Res. 2008;79(1):19–27.

CAS  PubMed  Google Scholar 

Vial PA, Valdivieso F, Ferres M, Riquelme R, Rioseco ML, Calvo M, et al. High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial. Clin Infect Dis. 2013;57(7):943–51.

CAS  PubMed  PubMed Central